A5100652912- Liver Disease Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis B Virus Studies
- Hepatitis C virus research
- Liver Disease and Transplantation
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pharmacological Effects of Natural Compounds
- Endoplasmic Reticulum Stress and Disease
- Cancer Genomics and Diagnostics
- Organ Transplantation Techniques and Outcomes
- Cancer Mechanisms and Therapy
- Ginseng Biological Effects and Applications
- Cancer, Lipids, and Metabolism
- Liver physiology and pathology
- Liver Diseases and Immunity
- Cancer, Hypoxia, and Metabolism
- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- Hepatitis Viruses Studies and Epidemiology
- Neuroendocrine Tumor Research Advances
- Gastric Cancer Management and Outcomes
- Natural product bioactivities and synthesis
- Immunotherapy and Immune Responses
- Drug-Induced Hepatotoxicity and Protection
- Gastrointestinal Tumor Research and Treatment
Seoul National University
2016-2025
Seoul National University Hospital
2016-2025
Rural Development Administration
2015-2025
Samaritan Health Services
2025
Myongji Hospital
2013-2024
Korea University
2021-2024
New Generation University College
2012-2024
National University College
2010-2024
Science and Technology Corporation (Netherlands)
2024
University of Hong Kong
2024
No adjuvant therapy has been shown to extend the survival of patients with hepatocellular carcinoma (HCC) receiving curative treatment. We investigated whether injections activated cytokine-induced killer (CIK) cells (CD3+/CD56+ and CD3+/CD56- T CD3-/CD56+ natural cells) prolongs recurrence-free after for HCC.We performed a multicenter, randomized, open-label, phase 3 trial efficacy safety immunotherapy CIK (created by incubation patients' peripheral blood mononuclear interleukin 2 an...
To determine the efficacy and safety of transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) main portal vein (MPV) invasion.This study was approved by institutional review board, requirement to obtain informed consent waived. The authors retrospectively assessed electronic medical records whom HCC MPV invasion newly diagnosed from January 2004 December 2007 at a single tertiary center. Patients decompensated hepatic function were excluded. Outcomes treated...
ABSTRACT Background Baseline viral replication activity influences the risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B virus (HBV) infection. Aims To evaluate impact baseline on recurrence HBV‐related HCC after curative resection. Methods A multinational retrospective cohort 2384 very early or early‐stage who consecutively underwent resection and received antiviral therapy (AVT) between 2010 2018 was analysed. Patients were categorised into ongoing‐AVT...
Abstract Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) are the major adult liver cancers. The existence of combined hepatocellular-cholangiocarcinoma (CHC), a histopathologic intermediate form between HCC CC, suggests phenotypic overlap these tumors. Here, we applied an integrative oncogenomic approach to address clinical functional implications overlapping phenotype By performing gene expression profiling human HCC, CHC, identified novel subtype, i.e., cholangiocarcinoma-like...
Goal In this study, we attempted to evaluate the prognosis of combined hepatocellular and cholangiocarcinoma (cHCC-CC) with comparison carcinoma (HCC) intrahepatic (CC). Background The cHCC-CC has not been fully elucidated. HCC CC. Study Consecutive patients who underwent curative resection for at a single tertiary care center in Korea their age, sex, Child-Turcotte-Pugh class matched CC were included. We evaluated time-to-recurrence (TTR) overall survival (OS) cases compared them patients....
To develop and validate a model to predict tumor recurrence after living donor liver transplantation (LDLT) (MoRAL) for hepatocellular carcinoma (HCC) beyond the Milan criteria (MC).Some subgroups of HCC exceeding MC experience substantial benefit from LDLT.This multicenter study included total 566 consecutive patients who underwent LDLT in Korea: beyond-MC cohort (n = 205, derivation [n 92] validation 113] sets) within-MC 361). The primary endpoint was time-to-recurrence.Using multivariate...
Hepatocellular carcinoma harbors numerous genomic and epigenomic aberrations of DNA copy numbers methylation. Transcriptomic deregulation by these plays key driver roles in heterogeneous progression cancers. Here, we profile numbers, methylation, messenger RNA expression levels from 64 cases hepatocellular specimens. We find that the frequencies aberrancies copy-number-correlated (CNVcor) genes methylation-correlated (METcor) are co-regulated significantly. Multi-omics integration CNVcor...
Purpose To compare the effectiveness of transarterial chemoembolization (TACE), radiofrequency ablation (RFA), and hepatic resection (HR) in patients with small single-nodule hepatocellular carcinoma by using inverse probability weighting to control selection bias. Materials Methods This retrospective cohort study was approved institutional review board, requirement obtain informed consent waived. The included 197 consecutive (146 men 51 women; mean age ± standard deviation, 57.4 years 9.7)...
Nonalcoholic fatty liver disease (NAFLD) is associated with visceral obesity. However, the association between adipose tissue (VAT) area and fibrosis in NAFLD patients has not been completely established. This study was aimed to determine relationship computed tomography-measured VAT significant patients. A total of 324 132 controls were evaluated by biopsy. diagnosed based on histological examinations alcohol consumption <20 g/day. The showed a higher age gender-adjusted than control group...
Antiplatelet therapy has shown protective effects against hepatocellular carcinoma (HCC) in preclinical studies. However, it is unclear whether antiplatelet lowers the risk of HCC patients with chronic hepatitis B. A retrospective analysis was conducted data from 1,674 B patients, enrolled between January 2002 and May 2015, whose serum virus DNA levels were suppressed by antivirals to <2,000 IU/mL. The primary secondary outcomes development bleeding events, respectively. Risk compared...
Hepatitis B virus (HBV) infection is the predominant risk factor for chronic hepatitis (CHB), liver cirrhosis (LC) and hepatocellular carcinoma (HCC). Recently, several genome-wide association studies (GWASs) of CHB identified human leukocyte antigen (HLA) loci, including HLA-DP HLA-DQ in Asian populations, as being associated with CHB. To confirm identify host genetic factors related to infection, we performed another GWAS using a higher-density chip Korean carriers. We analyzed 1400...
Rifaximin might decrease the risk of portal hypertension-related complications by controlling small intestinal bacterial overgrowth.To evaluate whether rifaximin was associated with death and cirrhotic complications.We conducted a retrospective study that included 1042 patients experiencing hepatic encephalopathy (HE): 421 without hepatocellular carcinoma (HCC; non-HCC cohort) 621 HCC (the cohort). The primary endpoint overall survival secondary endpoints were recurrence HE development...
Synergistic effect of radiotherapy and immunotherapy for the treatment hepatocellular carcinoma (HCC) has been reported. This phase I/IIa pilot trial evaluated preliminary efficacy safety combination radioembolization with yttrium-90 microspheres (Y90-radioembolization) durvalumab in patients locally advanced unresectable HCC.Patients Child-Pugh score ≤ 7 HCC, defined as Barcelona Clinic Liver Cancer (BCLC) stage B HCC or BCLC-C disease without extrahepatic metastases, received...
No medication has been found to reduce liver-related events. We evaluated the effect of sodium-glucose cotransporter-2 inhibitor (SGLT2i) on outcomes.